We are recruiting a technical assistant to join our work on establishing a research program on epigenome-based precision medicine focusing on bone tumors in children. Our lab is based at the Children's Cancer Research Institute (CCRI) of the St. Anna Kinderkrebsforschung Association in Vienna (Austria). The Institute is located in the heart of beautiful Vienna, a European metropolis full of history, music and fine arts. Vienna has been voted “most livable” city in the world for the 4th year in a row. CCRI is a renowned research institution with tight links to the St. Anna Children's Hospital, a leading pediatric cancer center in Europe and well connected through various European and international networks. The ultimate aim of our research at CCRI is to improve treatment outcome of malignant diseases in children and adolescents by performing basic, translational and clinical research. Additional information on the CCRI can be found at http://science.ccri.at/
• Bachelor or Master degree (or equivalent) in life sciences with strong wet-lab experience
• High accuracy, reliability, precision under time pressure, and strong organizational skills
• High motivation and commitment, proactive mindset, getting-things-done attitude
• Friendly, collaborative mindset and ability to work well in an international environment
• Experience with DNA/RNA assays including library preparation for next generation sequencing is a plus
• Excellent tissue culture skills working with cancer cell lines and primary human cells
• Written and oral communication skills in both English and German are required
• Contribute wet-lab work and expertise to collaborative research projects
• Optimization and testing of new protocols, e.g. for epigenome editing
• Actively participate in group meetings and scientific discussions
• Contribute to the preparation of scientific manuscripts
• Lab management, e.g. ordering and maintenance of lab inventories
• Training of new lab members in established and new protocols
Under the leadership of Eleni M. Tomazou, the Epigenome-based Precision Medicine lab at CCRI dissects the role of epigenetic aberrations in tumor initiation, progression and resistance to therapy, with the aim to provide tailored therapies for hard-to-treat childhood cancers such as Ewing sarcoma. By applying state-of-the-art epigenomics and novel bioinformatic tools, we have introduced a novel concept in the field of pediatric sarcoma:
Ewing sarcoma is an enhancer disease characterized by widespread epigenetic heterogeneity.
This novel concept is the backbone of our ongoing work towards:
- Understanding the mechanism(s) of Ewing sarcoma initiation, progression and resistance to therapy
- Establishing novel therapeutic paradigms for pediatric sarcoma
- Developing biomarkers for patient stratification to inform future clinical trials
Applications including motivation letter, curriculum vitae, academic transcripts and contact details of three referees should be sent by e-mail to Eleni Tomazou, email: hr(at)ccri.at. The application deadline is 2 March 2018. The position is available immediately. Successful applicants will be offered a competitive salary scheme with a minimum payment of € 2,600 (14 times per year).
Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schönegger A, Schuster M, Hadler J, Guillemot D, Lapouble E, Freneaux P, Champigneulle J, Bouvier R, Walder D, Ambros IM, Hutter C, Sorz E, Amaral AT, Álava Ed, Schallmoser K, Strunk D, Rinner B, Liegl-Atzwanger B, Huppertz B, Leithner A, Pinieux Gd, Terrier P, Laurence V, Michon J, Ladenstein R, Holter W, Windhager R, Dirksen U, Ambros PF, Delattre O, Kovar H, Bock C, Tomazou EM. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nature Medicine. 2017 Mar;23(3):386-395.
Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schönegger A, Datlinger P, Kubicek S, Bock C, and Kovar H. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Reports. 2015 Feb 24;10(7):1082-95